Prima hires Progen for vaccine manufacture
10 October, 2003 by Tanya HollisBrisbane's Progen Industries (ASX:PGL) will take on production of an anti-cancer therapeutic vaccine for Prima Biomed's (ASX:PRR) Cancer Vac subsidiary.
AGT boss touts genes' athletic implications
10 October, 2003 by Tanya HollisAustralian researchers have discovered two genes that are critical to understanding elite athletic performance, an Athens conference has heard.
Biogen using Brain Resource Co platform
10 October, 2003 by Tanya HollisSydney-based Brain Resource Company (ASX:BRC) has cracked into the biotechnology sector with a deal to provide its profiles of brain function and cognition to Biogen in the United States.
Visiomed in spinal surgery collaboration
10 October, 2003 by Tanya HollisDiagnostics group Visiomed (ASX:VSG) has entered a German research collaboration to develop surgical navigation systems for spinal procedures.
Abbott disputes Peptech patent infringement
08 October, 2003 by Melissa TrudingerPeptech's shares (ASX:PTD) nose-dived today, dropping as low as AUD$1.23 after news that the company was embroiled in another patent dispute over its anti-TNF patents, this time with licensee Abbott Laboratories.
Norwood on track for spin-off's UK listing
08 October, 2003 by Tanya HollisNorwood Abbey (ASX:NAL) is on track to list its immunology spin-off in the United Kingdom within six months.
GroPep finally closes Biotech Australia chapter
07 October, 2003 by Melissa TrudingerGroPep (ASX:GRO) has closed the book on its acquisition of Biotech Australia with the receipt of AUD$3.6 million final payment for the Roseville site.
ComBio 2003: The hard truth about salt resistance
07 October, 2003 by Graeme O'Neill'Durum' means 'hard' in Latin -- but for wheatgrowers who have tried to grow high-value, high-protein durum wheats in the semi-arid regions of Victoria, SA an WA semi-arid zone, durum wheats are in the too-hard basket.
Biotech demand will continue to grow: analyst
07 October, 2003 by Melissa TrudingerThe recent upswing in biotech share prices has acted as a trigger point for the increase in investment in the sector, according to sector analyst and BioShares co-editor David Blake.
Ventracor to benefit from US reimbursement decision
03 October, 2003 by Tanya HollisA United States decision to approve reimbursement of Ventricular Assist Devices has come as good news to Australian artificial heart developer Ventracor (ASX:VCR).
pSivida raises $6.5m, raises stake in UK subsid
03 October, 2003 by Tanya HollisBiomedical nanotechnology company pSivida (ASX:PSD) will strengthen its stake in its United Kingdom operating subsidiary following a AUD$6.5 million capital raising, the biotech announced today.
Biota strengthens Sankyo agreement
03 October, 2003 by Tanya HollisBiota Holdings' (ASX:BTA) second-generation influenza program has leap-frogged into clinical trials thanks to a partnership with a Japanese competitor.
UK investors double EQiTX war chest
02 October, 2003 by Tanya HollisTechnology investment company EQiTX (ASX:EQX) has more than doubled its cash reserves with a successful AUD$2.7 million capital raising, raised mostly through investors in the United Kingdom.
BioDiem options eye treatment peptide
02 October, 2003 by Tanya HollisMelbourne pharmaceutical development company BioDiem has taken an option over research involving the use of a peptide to treat major retinal diseases and age-related blindness.
Monsanto opens Qld research centre
01 October, 2003 by Melissa TrudingerMonsanto has opened a biotechnology research centre in Queensland to support its cotton product stewardship program.
